Monitoring of AZA/6-MP treatment in children with IBD is necessary.
Dubinsky
Marla C
MC
Pediatric Gastroenterology, Cedars-Sinai Hospital, Los Angeles, CA 90048, USA. marla.dubinsky@cshs.org
D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D016903:Drug Monitoring; D006150:Guanine Nucleotides / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*; D008778:Methylthioinosine / Q000032:analysis; D008780:Methyltransferases / Q000032:analysis / Q000235:genetics; D011110:Polymorphism, Genetic; D013873:Thionucleotides / Q000032:analysis
D006150:Guanine Nucleotides; D007166:Immunosuppressive Agents; D013873:Thionucleotides; C003964:6-thioguanylic acid; D008778:Methylthioinosine; D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D001379:Azathioprine